AURA-ADNCT07527923
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
At risk: Primary completion moved 52 days later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 11 words
- Primary and study completion pushed from Jun 23, 2028 to Aug 14, 2028
- Enrollment increased: 144 → 160 participants
- Trial sites expanded: 5 → 9 locations
- Minor Study sites: 5 to 7
- Notable Eligibility criteria expanded, about 14 words
- Trial sites expanded: 1 → 5 locations
- Secondary endpoints: details revised at 2 of 25 entries
Notable Recruitment openedv2 Show 5 more changesShow less
- Enrollment target: 136 to 144
- Study sites: 0 to 1
- Primary and study completion dates: Jun 9, 2028 to Jun 23, 2028
- Start date changed from estimate of May 4, 2026 to May 22, 2026
- Secondary endpoints revised (25)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Timeframe: Up to 69 weeks
Severity of TEAEs
Timeframe: Up to 69 weeks
Secondary (25)
Concentrations of REGN20423 in serum
Absolute values from baseline of total Interleukin 13 (IL-13)
Absolute values from baseline of total Immunoglobulin E (IgE)
Absolute values from baseline of total eosinophil counts in blood
Absolute values from baseline of total periostin
Show 20 moreShow less
Absolute values from baseline of total Thymus and Activation-Regulated Chemokine (TARC)
Percent change from baseline of total IL-13
Percent change from baseline of total IgE
Percent change from baseline of total eosinophil counts in blood
Percent change from baseline of total periostin
Percent change from baseline of total TARC
Occurrence of Anti-Drug Antibodies (ADA) to REGN20423
Magnitude of ADA to REGN20423
Absolute change from baseline in Eczema Area and Severity Index (EASI) score
Percent change from baseline in EASI score
Achievement of EASI-50
Achievement of EASI-75
Achievement of EASI-90
Achievement of Investigator's Global Assessment (IGA) 0-1
Achievement of IGA 0-1 with reduction in IGA score by ≥2
Achievement of a reduction in IGA score by ≥2
Absolute change from baseline in % Body Surface Area (BSA)
Absolute change from baseline in EASI
Percent change from baseline in % BSA
Percent change from baseline in EASI
Arms and interventions
Part AExperimental
Part BExperimental
Drugs: REGN20423
Other: Placebo
Sites
9 sites in 2 countries
United States 8, Belgium 1